全文获取类型
收费全文 | 323篇 |
免费 | 30篇 |
学科分类
医药卫生 | 353篇 |
出版年
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2015年 | 5篇 |
2014年 | 3篇 |
2013年 | 6篇 |
2012年 | 16篇 |
2011年 | 13篇 |
2010年 | 2篇 |
2009年 | 5篇 |
2008年 | 7篇 |
2007年 | 8篇 |
2006年 | 14篇 |
2005年 | 10篇 |
2004年 | 8篇 |
2003年 | 11篇 |
2002年 | 12篇 |
2001年 | 9篇 |
2000年 | 12篇 |
1999年 | 22篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 7篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 18篇 |
1991年 | 14篇 |
1990年 | 14篇 |
1989年 | 9篇 |
1988年 | 13篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 3篇 |
1984年 | 12篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1971年 | 1篇 |
1970年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有353条查询结果,搜索用时 15 毫秒
41.
Pascale Loiseau Marc Busson Marie-Lorraine Balere Anne Dormoy Jean-Denis Bignon Katia Gagne Lucette Gebuhrer Valérie Dubois Isabelle Jollet Monique Bois Pascale Perrier Dominique Masson Agnès Moine Léna Absi Denis Reviron Virginia Lepage Ryad Tamouza Antoine Toubert Evelyne Marry Zina Chir Jean-Pierre Jouet Didier Blaise Dominique Charron Colette Raffoux 《Biology of blood and marrow transplantation》2007,13(8):965-974
HLA matching between the donor and recipient improves the success of unrelated hematopoietic stem cell transplantation (HSCT). Because many patients in need of an unrelated transplant have only donors with mismatch, information is needed to evaluate the limits of HLA mismatching. We examined the association of survival, acute graft-versus-host disease (aGVHD) and relapse with HLA-A, -B, -C, -DRB, -DQB1, and -DPB1 mismatching in 334 patients coming from 12 French transplant centers and who received a non-T cell-depleted bone marrow graft from an unrelated donor. All patients were prepared with the use of myeloablative conditioning regimens. Our analyses demonstrate negative effects of HLA mismatching for either HLA-A, -B, -C, -DRB1, or -DQB1 loci on survival. Multivariate Cox analyses showed that a single mismatch was associated with a significant decrement in survival (P=.046, hazard ratio [HR]=1.41, confidence interval [CI] 95% 1.1-1.98). The presence of multiple mismatches was worse for survival (P=.003, HR=1.91, CI 95% 1.26-2.91) and severe aGVHD (grade III-IV) (P=.002, HR=2.51, CI95% 1.41-4.46). The cumulative incidences of aGVHD and relapse in those HLA-A, -B, -C, -DRB1, and -DQB1 identical pairs with 2, 1, or 0 DPB1 incompatibilities were 63%, 50%, and 51%, and 12%, 27%, and 20%, respectively, but these differences were not statistically significant. Similar differences of aGVHD and relapse, but not statistically significant, were observed in those HLA-A, -B, -C, -DRB1, and -DQB1 identical pairs with DPB1 disparities classified into permissive or nonpermissive mismatches according to Zino's classification based on a hierarchy of the immunogenicity of the HLA-DP molecules. "Missing killer cell immunoglobulin-like receptor (KIR) ligand" evaluated on the presence of HLA-C1, -C2, and Bw4 groups in the recipients was not associated with aGVHD, survival, and relapse in this cohort of non-T cell-depleted HSCT. 相似文献
42.
C R Lambré S le Maho G di Bella H de Cremoux K Atassi J Bignon 《The American review of respiratory disease》1986,134(2):238-242
In this work, using bronchoalveolar lavage fluids (BALF), we demonstrated the presence of complement within airways by assaying hemolytic activity of the whole classical pathway (CH50) and by measuring the complement component C2 (C2H50). Patients with sarcoidosis, patients with idiopathic pulmonary fibrosis (IPF), and healthy control subjects were compared. No CH50 activity was found in BALF from healthy control subjects (n = 9), but some activity (mean, 20 CH50) was associated with IPF (n = 7). Complement activities ranged from 40 to 554 CH50 in patients with sarcoidosis (n = 27). During the treatment, complement activity decreased in BALF from the few patients in our series who received corticotherapy. C2 hemolytic activity was detected in BALF from the normal control group (in the absence of CH50 activity). In the sarcoidosis and IPF groups when CH50 was present, the variations in the C2/CH50 ratio were studied. The high ratio observed in BALF from patients with sarcoidosis and a chronic derangement of alveolar structure suggests either an increased C2 production or an alternative complement pathway (C2-independent) activation within their lungs. 相似文献
43.
BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer 下载免费PDF全文
Nagi S. El Saghir Nathalie K. Zgheib Hussein A. Assi Katia E. Khoury Yannick Bidet Sara M. Jaber Raghid N. Charara Rania A. Farhat Firas Y. Kreidieh Stephanie Decousus Pierre Romero Georges M. Nemer Ziad Salem Ali Shamseddine Arafat Tfayli Jaber Abbas Faek Jamali Muhieddine Seoud Deborah K. Armstrong Yves‐Jean Bignon Nancy Uhrhammer 《The oncologist》2015,20(4):357-364
Purpose.
Breast cancer is the most common malignancy among women in Lebanon and in Arab countries, with 50% of cases presenting before the age of 50 years.Methods.
Between 2009 and 2012, 250 Lebanese women with breast cancer who were considered to be at high risk of carrying BRCA1 or BRCA2 mutations because of presentation at young age and/or positive family history (FH) of breast or ovarian cancer were recruited. Clinical data were analyzed statistically. Coding exons and intron-exon boundaries of BRCA1 and BRCA2 were sequenced from peripheral blood DNA. All patients were tested for BRCA1 rearrangements using multiplex ligation-dependent probe amplification (MLPA). BRCA2 MLPA was done in selected cases.Results.
Overall, 14 of 250 patients (5.6%) carried a deleterious BRCA mutation (7 BRCA1, 7 BRCA2) and 31 (12.4%) carried a variant of uncertain significance. Eight of 74 patients (10.8%) aged ≤40 years with positive FH and only 1 of 74 patients (1.4%) aged ≤40 years without FH had a mutated BRCA. Four of 75 patients (5.3%) aged 41–50 years with FH had a deleterious mutation. Only 1 of 27 patients aged >50 years at diagnosis had a BRCA mutation. All seven patients with BRCA1 mutations had grade 3 infiltrating ductal carcinoma and triple-negative breast cancer. Nine BRCA1 and 17 BRCA2 common haplotypes were observed.Conclusion.
Prevalence of deleterious BRCA mutations is lower than expected and does not support the hypothesis that BRCA mutations alone cause the observed high percentage of breast cancer in young women of Lebanese and Arab descent. Studies to search for other genetic mutations are recommended. 相似文献44.
Francesca Damiola Inès Schultz Laure Barjhoux Valérie Sornin Marie-Gabrielle Dondon Séverine Eon-Marchais Morgane Marcou Olivier Caron Marion Gauthier-Villars Antoine de Pauw Elisabeth Luporsi Pascaline Berthet Capucine Delnatte Valérie Bonadona Christine Maugard Pascal Pujol Christine Lasset Michel Longy Yves-Jean Bignon Jean-Pierre Fricker Nadine Andrieu Olga M. Sinilnikova Dominique Stoppa-Lyonnet Sylvie Mazoyer Danièle Muller The GENESIS Study Investigators 《Breast cancer research and treatment》2015,152(3):463-476
45.
The liver in alpha 1-antitrypsin deficiency 总被引:4,自引:0,他引:4
46.
Background and aims Mutations in DNA mismatch repair genes are associated with high risk of digestive malignancies [hereditary non-polyposis colorectal
cancer (HNPCC); Lynch syndrome]; mutations of APC and MYH are associated with classic and attenuated familial adenomatous polyposis (FAP). Although the early onset of tumors in both
syndromes is characteristic of their genetic origin, pediatric malignancies remain rare. Certain reports have found familial
colorectal cancer (CRC) occurring in very young patients associated with mutations in more than one gene.
Materials and method A family corresponding to the Amsterdam criteria for HNPCC, including two cases of colorectal cancer before the age of 25 years,
was analyzed for mutations in the MSH2 genes by sequencing. Because polyposis was observed in a patient who developed CRC
at age 16, the APC gene was also sequenced.
Results A truncating mutation in the MSH2 gene, c.258_259delTG, was carried by patients developing cancer of the colon (two patients), uterus, kidney, bladder, and/or
small intestine at ages 16, 24, 43, 44, 45, and 57, respectively. A patient with CRC at age 16 was found to carry the APC
c.3183_3187del5 mutation as well as the MSH2 mutation, and it is inferred that her father, deceased of CRC at age 24, was also a double heterozygote.
Interpretation These results confirm that vigilance is required when interpreting molecular results for families with very young patients,
as more than one gene may contribute to the genetic risk. Cancer screening measures must also be adapted to the earlier and
more penetrant risk to double heterozygotes. 相似文献
47.
48.
49.
50.
Patricia Fromont Nolwen Prié Philippe Simon Anne Cesbron‐Gautier Erwann Quelvennec Jean‐Denis Bignon Jean‐Yves Muller Marie Audrain 《Transfusion》2010,50(12):2643-2648
BACKGROUND: Granulocyte antibodies have been implicated in allo‐ and autoimmune neutropenia and in transfusion reactions. STUDY DESIGN AND METHODS: Fifty‐one sera from suspected alloimmune neutropenia or transfusion‐related acute lung injury (TRALI) and 40 sera from suspected autoimmune neutropenia were tested for granulocyte antibodies using LABScreen MULTI (One Lambda, Inc.), compared with classical tests (flow cytometry [FC] and granulocyte agglutination [GAT] followed by monoclonal antibody–specific immobilization of granulocyte antigens [MAIGA]). RESULTS: In alloimmune situations, 48 sera were concordant (94%), two sera positive for HNA with LABScreen MULTI were negative by FC/GAT and/or MAIGA, and one serum sample negative for HNA with LABScreen MULTI was positive by classical tests. In autoimmune neutropenia, 30 sera were concordant (75%), four sera positive for HNA with LABScreen MULTI were negative by FC/GAT and/or MAIGA, and six sera negative for HNA with LABScreen MULTI were positive by FC/GAT and/or MAIGA. For detection of autoantibodies, the LABScreen MULTI was less concordant. However, with the exception of one case, the discrepancies were observed in sera that did not show a clear specificity. CONCLUSIONS: LABScreen MULTI correlated well with our classical methods for HNA‐1 and HNA‐2a antibody screening. It can be used for screening blood donors or patients suspected of TRALI, but GAT is still needed for HNA‐3a antibody screening. 相似文献